SUMMARY A single oral dose of 3 g cefaclor was effective in the treatment of uncomplicated gonococcal infection in women due to penicillinase-producing strains of Neisseria gonorrhoeae (PPNG). Cefaclor was equally active in vitro against both PPNG (MIC range, 0 01-IOMg/ml) and non-PPNG strains (MIC range, 0O005-2 O,ug/ml). As empirical treatment cefaclor was effective in 53 of 57 (93%) patients compared with ampicillin, to which only 37 of 53 (69 8%) patients responded. This difference was attributed to the 407o incidence of PPNG in the patients studied; as expected, such patients responded poorly to ampicillin.
Introduction
Patients and methods
Cefaclor is an acid-stable semisynthetic cephalosporin which differs from its parent substance, cephalexin, in the substitution of a chloro group in the 3 position. Like cephalexin, cefaclor is absorbed orally but has the advantage of greater in-vitro activity against pathogens, particularly Haemophilus influenzae and Neisseria gonorrhoeae and their P-lactamase-positive strains.' 2 Compared with other cephalosporins cefaclor was second only to cefuroxime in its activity against N gonorrhoeae.2
Preliminary studies of the treatment of gonococcal urethritis in men have shown cefaclor to be effective in doses ranging from 2-4g with or without probenecid.3 Its efficacy in infections with penicillinaseproducing N gonorrhoeae (PPNG) has not yet been studied. The purpose of this study was to determine the efficacy of cefaclor in the treatment of uncomplicated gonococcal infections in women, particularly those due to PPNG. The results of empirical treatment of gonococcal infection with this drug were compared to those with the standard oral dose of ampicillin. Minimum inhibitory concentrations Prostitutes with uncomplicated gonococcal infection confirmed by culture on screening volunteered to join the study after the protocol had been explained. Written informed consent was obtained and the study was Complete blood cell count, urine analysis, and serum alanine aminotransferase (ALT), blood urea nitrogen, and serum creatinine concentrations were determined before treatment and 24 hours later.
Results

STUDY POPULATION
A total of 122 patients were initially enrolled in the study; those in each treatment group were comparable for age, weight, and sexual exposure. Since penicillinase production of the infecting strain could not be determined from the pretreatment culture at the time of the patient's inclusion into the study, the patients were not grouped according to this criterion. Thus, using random allocation, it was solely by chance that more patients with PPNG strains were assigned to the cefaclor treatment group.
Twelve patients, including four given cefaclor and eight given ampicillin, were excluded from the study because of negative pretreatment culture results. Interestingly, in one such patient given cefaclor with a negative pretreatment culture result, post-treatment cultures from the cervix and rectum subsequently gave a heavy growth of PPNG. Despite the precautions taken against reinfection during the study, this could not be totally excluded, as the patient may have left the clinic without the knowledge of the clinic staff.
The ages of the remaining 110 patients ranged from 15 to 34 years with a mean of 20 years, and weights ranged from 36 3 kg to 61 * 3 kg with a mean of 45 -5 kg. Thirty-eight of 110 (34 5 7o) patients were symptomatic; 44 patients were infected with PPNG and 66 with non-PPNG strains of N gonorrhoeae. Twenty-seven of the former and 30 of the latter were treated with cefaclor and the remainder received ampicillin. 
